Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma

作者：Anca Prica, Mark Roschewski, Peter Beale, Stefania Pittaluga, Jan Delabie, Claudia Ortega, Robert Kridel · 发表于：New England Journal of Medicine · 年份：2025 · DOI：10.1056/nejmc2501018 · 被引用次数：12 · 研究领域：Lymphoma Diagnosis and Treatment、Cutaneous lymphoproliferative disorders research、CNS Lymphoma Diagnosis and Treatment

Relapsed Burkitt’s lymphoma is nearly always fatal. Three patients had a complete metabolic response with the combination of the bispecific antibody glofitamab and the antibody–drug conjugate polatuzumab vedotin.